Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
What’s Next For Cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura Expands Roginolisib Trials to the US
Industry Insight
iOnctura Enhances Board to Accelerate Growth and Innovation
Industry Insight
Addressing Drug Resistance in Non-Small Cell Lung Cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
All news
Press coverage
FirstWord Pharma – With fresh €80M in hand, iOnctura looks to chart new PI3K path
Press release
€80 million Series B financing to progress pipeline through Phase II trials
Data & publication
Roginolisib: an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3kδ) in patients with uveal melanoma and advanced cancers
Press release
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
Data & publication
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Data & publication
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nabpaclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Data & publication
Preclinical activity of novel TGF beta receptor I kinase Inhibitors IOA-359 and IOA-360 for treatment of anemia in MDS/AML
Data & publication
Novel PI3Kδ inhibitor roginolisib synergizes with the Bcl-2 inhibitor venetoclax in hematological malignancies
Press release
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023
Data & publication
Safety and clinical efficacy of roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase Inhibitor delta (PI3Kδ)
Press coverage
pharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients
Press coverage
Immuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways
Looking for media
resources?